BioVie (BIVI) Competitors

BioVie (NASDAQ:BIVI) and IO Biotech (NASDAQ:IOBT) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their community ranking, risk, valuation, analyst recommendations, institutional ownership, media sentiment, earnings, profitability and dividends.

Does the media favor BIVI or IOBT?

In the previous week, IO Biotech had 3 more articles in the media than BioVie. MarketBeat recorded 6 mentions for IO Biotech and 3 mentions for BioVie. BioVie's average media sentiment score of 0.96 beat IO Biotech's score of 0.91 indicating that BioVie is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BioVie	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
IO Biotech	1 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Which has stronger valuation & earnings, BIVI or IOBT?

IO Biotech is trading at a lower price-to-earnings ratio than BioVie, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioVie	N/A	N/A	-$32.12M	-$9.76	-0.09
IO Biotech	N/A	N/A	-$86.08M	-$1.37	-0.74

Is BIVI or IOBT more profitable?

IO Biotech's return on equity of -86.56% beat BioVie's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioVie	N/A	-134.07%	-93.44%
IO Biotech	N/A	-86.56%	-75.24%

Which has more risk and volatility, BIVI or IOBT?

BioVie has a beta of 0.64, indicating that its share price is 36% less volatile than the S&P 500. Comparatively, IO Biotech has a beta of 0.08, indicating that its share price is 92% less volatile than the S&P 500.

Do insiders & institutionals believe in BIVI or IOBT?

4.6% of BioVie shares are held by institutional investors. Comparatively, 54.8% of IO Biotech shares are held by institutional investors. 4.0% of BioVie shares are held by company insiders. Comparatively, 2.3% of IO Biotech shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Do analysts recommend BIVI or IOBT?

BioVie currently has a consensus target price of $3.00, indicating a potential upside of 248.03%. IO Biotech has a consensus target price of $9.33, indicating a potential upside of 824.09%. Given IO Biotech's higher possible upside, analysts plainly believe IO Biotech is more favorable than BioVie.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioVie	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	3.50
IO Biotech	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	3.33

Does the MarketBeat Community favor BIVI or IOBT?

IO Biotech received 7 more outperform votes than BioVie when rated by MarketBeat users. Likewise, 92.59% of users gave IO Biotech an outperform vote while only 66.67% of users gave BioVie an outperform vote.

Company	Underperform	Outperform
BioVie	Outperform Votes 18 66.67%	Underperform Votes 9 33.33%
IO Biotech	Outperform Votes 25 92.59%	Underperform Votes 2 7.41%

Summary

IO Biotech beats BioVie on 9 of the 15 factors compared between the two stocks.